Medicines: reclassify your product

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) provides this guidance on the reclassification of medicines within the UK, operating under the Human Medicines Regulations 2012. The framework defines the three legal categories of medicines: Prescription-only (POM), Pharmacy (P), and General Sales List (GSL). The central goal is to enhance public access to treatments while managing risks such as misdiagnosis, incorrect use, and adverse side effects. Key safety barriers prevent reclassification if a medicine remains dangerous without medical supervision or requires injection. Required actions for companies depend on whether the application is 'Simple' (analogous to an existing product) or 'Major' (new therapeutic areas). Simple applications follow standard variation procedures, while Major applications require a comprehensive clinical overview, a Risk Management Plan (RMP), and updated product labeling. These major requests are often subject to expert committee reviews and 21-day public consultations. This regulatory oversight, highlighted in a November 2024 webinar, ensures that any shift in classification is supported by robust clinical evidence and stakeholder input. The MHRA maintains a reclassification database covering the period from 1991 to 2026 to track these regulatory changes and ensure public safety remains protected throughout the switching process.